This talk is geared to all Swedish Orphan leadership as well as to investors considering exiting their position in the firm. I will break down why Swedish Orphan leadership may should not consider a stake in the firm. In spite of comparatively weak essential indicators, Swedish Orphan may actually be approaching a critical reversion point that can send shares even higher in February 2019. We consider Swedish Orphan not too risky. Swedish Orphan Biovi
owns Efficiency Ratio (i.e. Sharpe Ratio) of 0.0731 which indicates the firm had 0.0731% of return per unit of risk over the last 1 month. Our philosophy towards measuring volatility of a stock is to use all available market data together with stock specific technical indicators
that cannot be diversified away. We have found twenty-one technical indicators
for Swedish Orphan Biovitrum AB which you can use to evaluate future volatility of the company. Please validate Swedish Orphan Risk Adjusted Performance
of 0.2457, Coefficient Of Variation
of 757.02 and Semi Deviation
of 1.16 to confirm if risk estimate we provide are consistent with the epected return of 0.1256%.
fundamentals ideas swedish orphan healthcare pharmaceuticals and biosciences drug manufacturers - specialty & generic